These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 19903812)
61. Glycan Microheterogeneity at the PGT135 Antibody Recognition Site on HIV-1 gp120 Reveals a Molecular Mechanism for Neutralization Resistance. Pritchard LK; Spencer DI; Royle L; Vasiljevic S; Krumm SA; Doores KJ; Crispin M J Virol; 2015 Jul; 89(13):6952-9. PubMed ID: 25878100 [TBL] [Abstract][Full Text] [Related]
62. A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies. Doria-Rose NA; Georgiev I; O'Dell S; Chuang GY; Staupe RP; McLellan JS; Gorman J; Pancera M; Bonsignori M; Haynes BF; Burton DR; Koff WC; Kwong PD; Mascola JR J Virol; 2012 Aug; 86(15):8319-23. PubMed ID: 22623764 [TBL] [Abstract][Full Text] [Related]
63. Susceptibility to Neutralization by Broadly Neutralizing Antibodies Generally Correlates with Infected Cell Binding for a Panel of Clade B HIV Reactivated from Latent Reservoirs. Ren Y; Korom M; Truong R; Chan D; Huang SH; Kovacs CC; Benko E; Safrit JT; Lee J; Garbán H; Apps R; Goldstein H; Lynch RM; Jones RB J Virol; 2018 Dec; 92(23):. PubMed ID: 30209173 [TBL] [Abstract][Full Text] [Related]
64. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Wu X; Zhou T; Zhu J; Zhang B; Georgiev I; Wang C; Chen X; Longo NS; Louder M; McKee K; O'Dell S; Perfetto S; Schmidt SD; Shi W; Wu L; Yang Y; Yang ZY; Yang Z; Zhang Z; Bonsignori M; Crump JA; Kapiga SH; Sam NE; Haynes BF; Simek M; Burton DR; Koff WC; Doria-Rose NA; Connors M; ; Mullikin JC; Nabel GJ; Roederer M; Shapiro L; Kwong PD; Mascola JR Science; 2011 Sep; 333(6049):1593-602. PubMed ID: 21835983 [TBL] [Abstract][Full Text] [Related]
65. AIDS/HIV. A boost for HIV vaccine design. Burton DR; Weiss RA Science; 2010 Aug; 329(5993):770-3. PubMed ID: 20705840 [No Abstract] [Full Text] [Related]
66. A single residue within the V5 region of HIV-1 envelope facilitates viral escape from the broadly neutralizing monoclonal antibody VRC01. Guo D; Shi X; Arledge KC; Song D; Jiang L; Fu L; Gong X; Zhang S; Wang X; Zhang L J Biol Chem; 2012 Dec; 287(51):43170-9. PubMed ID: 23100255 [TBL] [Abstract][Full Text] [Related]
67. Characterization of the multiple conformational States of free monomeric and trimeric human immunodeficiency virus envelope glycoproteins after fixation by cross-linker. Yuan W; Bazick J; Sodroski J J Virol; 2006 Jul; 80(14):6725-37. PubMed ID: 16809278 [TBL] [Abstract][Full Text] [Related]
68. Characterization of a monoclonal antibody to a novel glycan-dependent epitope in the V1/V2 domain of the HIV-1 envelope protein, gp120. Doran RC; Morales JF; To B; Morin TJ; Theolis R; O'Rourke SM; Yu B; Mesa KA; Berman PW Mol Immunol; 2014 Nov; 62(1):219-226. PubMed ID: 25016576 [TBL] [Abstract][Full Text] [Related]
69. Development of a Stable MGAT1 Doran RC; Yu B; Wright M; O'Rourke SM; Yin L; Richardson JM; Byrne G; Mesa KA; Berman PW Front Immunol; 2018; 9():2313. PubMed ID: 30344523 [TBL] [Abstract][Full Text] [Related]
70. Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains. Fera D; Schmidt AG; Haynes BF; Gao F; Liao HX; Kepler TB; Harrison SC Proc Natl Acad Sci U S A; 2014 Jul; 111(28):10275-80. PubMed ID: 24982157 [TBL] [Abstract][Full Text] [Related]
71. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Caskey M; Klein F; Lorenzi JC; Seaman MS; West AP; Buckley N; Kremer G; Nogueira L; Braunschweig M; Scheid JF; Horwitz JA; Shimeliovich I; Ben-Avraham S; Witmer-Pack M; Platten M; Lehmann C; Burke LA; Hawthorne T; Gorelick RJ; Walker BD; Keler T; Gulick RM; Fätkenheuer G; Schlesinger SJ; Nussenzweig MC Nature; 2015 Jun; 522(7557):487-91. PubMed ID: 25855300 [TBL] [Abstract][Full Text] [Related]
72. Antibodies against Manalpha1,2-Manalpha1,2-Man oligosaccharide structures recognize envelope glycoproteins from HIV-1 and SIV strains. Luallen RJ; Agrawal-Gamse C; Fu H; Smith DF; Doms RW; Geng Y Glycobiology; 2010 Mar; 20(3):280-6. PubMed ID: 19920089 [TBL] [Abstract][Full Text] [Related]
73. Crystal structure of the HIV neutralizing antibody 2G12 in complex with a bacterial oligosaccharide analog of mammalian oligomannose. Stanfield RL; De Castro C; Marzaioli AM; Wilson IA; Pantophlet R Glycobiology; 2015 Apr; 25(4):412-9. PubMed ID: 25380763 [TBL] [Abstract][Full Text] [Related]
74. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Pejchal R; Doores KJ; Walker LM; Khayat R; Huang PS; Wang SK; Stanfield RL; Julien JP; Ramos A; Crispin M; Depetris R; Katpally U; Marozsan A; Cupo A; Maloveste S; Liu Y; McBride R; Ito Y; Sanders RW; Ogohara C; Paulson JC; Feizi T; Scanlan CN; Wong CH; Moore JP; Olson WC; Ward AB; Poignard P; Schief WR; Burton DR; Wilson IA Science; 2011 Nov; 334(6059):1097-103. PubMed ID: 21998254 [TBL] [Abstract][Full Text] [Related]
75. A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site. Li L; Wang XH; Williams C; Volsky B; Steczko O; Seaman MS; Luthra K; Nyambi P; Nadas A; Giudicelli V; Lefranc MP; Zolla-Pazner S; Gorny MK Mol Immunol; 2015 Aug; 66(2):364-74. PubMed ID: 25965315 [TBL] [Abstract][Full Text] [Related]